Upload
aron-simmons
View
213
Download
0
Tags:
Embed Size (px)
Citation preview
©2013 MFMER | slide-1
Cost Effectiveness:How Can We Do More With Less?Stephen P. Merry, MD, MPH, DTM&HAssistant Professor of Family MedicineMayo Clinic, Rochester
©2013 MFMER | slide-3
Learning Objectives
• Treat chronic diseases in adults and children in resource limited settings in a rational, cost-effective way.
• Follow an income and country GNP based protocol for hypertension, type 1 and 2 diabetes, hyperlipidemia, and coronary artery disease diagnosis and care.
• Design treatment protocols based on guiding principles of cost-effectiveness.
3
©2013 MFMER | slide-4
Medical Missionaries Behaving Badly
• Follow US treatment protocols
• “We shouldn’t treat them any differently than we’d want to be treated…”
• Treating chronic diseases regardless of benefit or cost
• Expensive testing• Expensive monitoring• Expensive meds• Frequent rechecks
©2013 MFMER | slide-5
5
The Summary Slide
Careful consideration of the whole care process from care access to care follow-up including all costs including harms and benefits coupled with compassion
Cost effective care
©2013 MFMER | slide-6
Disclaimer
• I’m a clinician• The following is a patient centric view on cost
effectiveness analysis
• I’m not an economist
©2013 MFMER | slide-7
7
Cost-Effective Health Care
• Caring for people in resource limited setting• Less tests, technology, meds; just the
essentials• Less specialists• Less physician driven – lifestyle/public health
primary• Avoid futility
• Person centered, coordinated, comprehensive care by an accessible primary care provider
©2013 MFMER | slide-8
Cost Effective Care
• Requires analysis of the “care delivery value chain”
• Prevention• Testing/Screening• Staging• Delaying progression of disease• Initiation of therapy• Continuous disease management• Management of deterioration
Rhatigan et al. Applying the Care Delivery Value Chain: HIV/AIDS Care in Resource Poor Setttings. Harvard Business School working paper, 2009
©2013 MFMER | slide-9
Cost Effectiveness Analysis
• Searches for “best buys”• E.g. smoking cessation vs statins for CVD
prevention.
• Expresses decisions in cost per benefit (usually cost in US$/DALY gained)
• Requires clear knowledge (rather than guesses) of numbers needed to treat for one to benefit
WHO and World Economic Forum, “From Burden to ‘Best Buys’”, 2009
©2013 MFMER | slide-10
What Is A Reasonable Cost?
• How much are they willing to pay for the estimated value of the treatment?
• What is 1 DALY worth• 3 x the per capita income • The income of the family / # in family?
©2013 MFMER | slide-11
Case 1:The Hypertensive Guinean Farmer
A 55 yo Guinean farmer from 2 hours away sees you for a rash on his feet. His exam reveals a BP 159/99 and is normal other than tinea pedis. He is a non-smoker, mildly obese (BMI 33) man without history of CAD, stroke, DM or symptoms of polyuria. In addition to Clotrimazole for his tinea, you would
a)Recommend lifestyle changes, BP checks by a VHW, and return if consistently elevated above 160/100.
b)Do “a” but start HCTZ daily now and ASA 81 mg daily.
c)Do “b” but check a potassium, creatinine, fasting glucose, U/A, CBC, and ECG
d)Do “c” and also check his cholesterol level and initiate statin if elevated.
e)Do “d” and also begin Metformin if diabetic.
©2013 MFMER | slide-12
What is HTN?JNC 7 and WHO
• Normal = systolic <120 mmHg and diastolic <80
• Pre-hypertension: systolic 120-139 or diastolic 80-89
• Hypertension:• Stage 1: systolic 140-159 or diastolic 90-99• Stage 2: systolic 160 or diastolic 100
©2013 MFMER | slide-13
Hypertension in Africa
0
2
4
6
8
10
12
14
16
18
% Detected % Treated % Controlled
Urban
Rural
Adapted from Edwards R, Unwin N, Mugusi F et al. Hypertension prevalence and care in an urban and rural area of Tanzania 2000. J Hypertens; 18:145-52.
©2013 MFMER | slide-14
HTN in Guinea
N'Gouin-Claih AP, Donzo M, Barry AB, Diallo A, Kabiné O, Barry R, Abdoulaye K, Sylla C, Magassouba FB, Baldé AM Prevalence of hypertension in Guinean rural areas Arch Mal Coeur Vaiss. 2003 Jul-Aug;96(7-8):763-7
0
10
20
30
40
50
60
70
% Adults HTN % On Treatment
Kopere-Dofili
Tobolon
©2013 MFMER | slide-15
Should we treat mild HTN?
• > 140/90 even if no risk factors?
• NNT for 1 year = 700 to prevent 1 MI or stroke related death (mild HTN).
• If cost of Rx = US$50/year, is the Guinean farmer REALLY consenting to US $35,000 to save ?10 years life (WHO suggests max cost should be 3 x per capita GNP or about $1300 for Guinea)?
• Paternalism vs. shared decision making.
©2013 MFMER | slide-18
Initial Evaluation of HTN
• Labs• Dip U/A; maybe other if history, exam or
urinalysis suggests need and can afford.• Creatinine• K+• (ECG)• (Lipids)• (Fasting blood sugar)
©2013 MFMER | slide-19
Who to Treat?
• WHO & JNC 7 : > 140/90 or >130/80 in renal disease
• Depends…• Access to care and follow up• Availability/cost of meds• Co-morbidity• Household finances
• Risk-Based treatment with full informed consent
©2013 MFMER | slide-20
Who to Treat?Isolated Systolic HTN?
• Systolic > 160 (Diast < 95).• NNT 5 years to prevent a major CV event
• 18 men; 38 women• 19 elderly > 70; 39 < 70 yo• 16 people with prior CV disease• So, have to treat about 20 people for 5 years to
prevent one CV event or 100 people for 1 year• NNT/year = 100• Cost to prevent an event in Africa = US$50/year
(cheapest method of treatment!) x 100 = US$5,000 to prevent a fatal MI or stroke
Staessen JA. Lancet 2000; 355(9207): 865-72
©2013 MFMER | slide-21
Wait…Are You Saying Life Isn’t Worth That?
• No…
• Examine the total costs per benefit.
• Where is that money coming from • Children’s nutrition• Wife’s prenatal care
©2013 MFMER | slide-22
Choose Meds & Methods Wisely
Start with Thiazide diuretics - cheap, few side effects• Hydrochlorthiazide 25 mg daily # 300 + 1
banana/day• “See me in 6 months” (or 1 year) – sooner if
high risk.• Annual check on co-morbidities, compliance,
refills, (dip urine).
©2013 MFMER | slide-24
Risk Stratification of hypertensive patients
Grade 1Grade 1
(140-159/90-(140-159/90-99 mm Hg)99 mm Hg)
Grade 2Grade 2
(160-179/100-(160-179/100-109 mm Hg)109 mm Hg)
Grade 3Grade 3
((≥≥ 180/110 180/110 mm Hg)mm Hg)
No risk factorsNo risk factors Low riskLow risk Medium riskMedium risk High riskHigh risk
1-2 risk factors1-2 risk factors Medium riskMedium risk Medium-high Medium-high riskrisk
Very high Very high riskrisk
≥ ≥ 3 risk factors, 3 risk factors, LVH, proteinuria, LVH, proteinuria, raised creatinine, raised creatinine, grade 2 retinopathy.grade 2 retinopathy.
High riskHigh risk High riskHigh risk Very high Very high riskrisk
Associated clinical Associated clinical condition condition = stroke, CAD, = stroke, CAD, CHF, CRF, DM neph, grade CHF, CRF, DM neph, grade 3+ hypertensive retinopathy3+ hypertensive retinopathy
Very high Very high riskrisk
Very high Very high riskrisk
Very high Very high riskrisk
Adapted from WHO Guidelines
©2013 MFMER | slide-25
The Big Idea:
• Patients/Families/Countries with more resources should be treated at earlier stages with fewer co-morbidities.
• If the Guinean Farmer is paying out of pocket, mild hypertension should not probably be treated.
©2013 MFMER | slide-26
Etiology of Heart Failure in a Urban Cardiology Practice in Africa(Ghana)
21%
20%
16% 10%10%
23%
Hypertension
Rheumatic HeartDisease
Cardiomyopathy
Congenital HeartDisease
Ischemic
Other
Amoah AG. Cardiology 2000; 93(1-2):11-8
©2013 MFMER | slide-27
How should we treat mild HTN or low risk patients?
• Depends… “Shared Decision Making”
• Diet• Low salt• High fruits and vegetables• Weight loss• Less alcohol
• Exercise
©2013 MFMER | slide-28
Lifestyle Modifications in the Management of Hypertension
ModificationModification RecommendationRecommendation Approximate systolic Approximate systolic BP reductionBP reduction
Weight reductionWeight reduction Maintain BMI 18.5 – Maintain BMI 18.5 – 2525
5-20 mm Hg per 10 lb 5-20 mm Hg per 10 lb lossloss
Adopt DASH eating Adopt DASH eating planplan
Diet rich in fruits, Diet rich in fruits, vegevege’’s, low fat dairy, s, low fat dairy, reduced sat. fatreduced sat. fat
8-14 mm Hg8-14 mm Hg
Dietary sodium Dietary sodium reductionreduction
Low salt diet – 2.4 gm Low salt diet – 2.4 gm sodiumsodium
2-8 mm Hg2-8 mm Hg
Physical activityPhysical activity 30 min per day brisk 30 min per day brisk activityactivity
4-9 mm Hg4-9 mm Hg
Limit alcoholLimit alcohol No more than 2/day No more than 2/day men and 1/day men and 1/day womenwomen
2-4 mm Hg2-4 mm Hg
Adapted from JNC 7
©2013 MFMER | slide-29
Patient Education - HTN
• HTN requires lifelong treatment
• HTN increases the risk of many diseases – stroke, heart attack, etc.
• HTN treatment won’t make you feel much better but it’s good for you.
• Lifestyle mod is AS IMPORTANT as medicine.
• You need to take your medicine daily.
©2013 MFMER | slide-30
Choose Meds Wisely
• Goal• Cheap• Convenient• Effective risk reduction• No side effects
©2013 MFMER | slide-31
Second Rx:Choose Meds Wisely
• All meds ~ same benefit in large studies (ALLHAT).
• Start with Thiazide diuretics - cheap, few side effects, superior in CHD prevention
• CCB’s work best in Africans
©2013 MFMER | slide-32
Antihypertensive Medication Response in US African Americans
Materson BJ, Reda DJ, Cushman WC, et al. NEJM 1993, 328:914
©2013 MFMER | slide-33
Choosing Meds Wisely
• Amlodipine or Verapamil cheap and effective second line
• CCB’s, Alpha-B’s, methyldopa, reserpine, hydralazine - effective without a Thiazide.
• B-blockers and ACE’s - made more effective in Africans with a Thiazide.
• Choose med based on co-morbidity e.g.• Start with ACE if DM2
• Expect a creatinine rise up to 0.3 mg/dl• Check creatinine and K+ after ~ 2 weeks
©2013 MFMER | slide-34
The ABCD’s of Choosing HTN Meds WiselyClass of DrugClass of Drug IndicationIndication Contraindication/Side Contraindication/Side
effects/effects/MonitoringMonitoring
Alpha-blocker (Hytrin)Alpha-blocker (Hytrin) BPHBPH Orthostatic hypotensionOrthostatic hypotension
ACE/ARB ***ACE/ARB ***
Lisinopril etcLisinopril etc
Diovan, Candesartan Diovan, Candesartan
CHF, DM CHF, DM nephropathy, renal nephropathy, renal diseasedisease
Cough (ACE), hyperK+, renal Cough (ACE), hyperK+, renal impairment.impairment.
K+ and Creatinine at 2 weeks, K+ and Creatinine at 2 weeks, annualannual
Beta-blockerBeta-blocker
(Atenolol, Metoprolol)(Atenolol, Metoprolol)
CAD, pregnancy, CAD, pregnancy, (CHF)(CHF)
CHF, brady, asthmaCHF, brady, asthma
Calcium blockerCalcium blocker
(Verapamil, Cardizem)(Verapamil, Cardizem)
CADCAD DonDon’’t use with B-blockert use with B-blocker
Calcium blockerCalcium blocker
(DHP class: Norvasc)(DHP class: Norvasc)
CAD, isolated CAD, isolated systolic HTN in systolic HTN in elderlyelderly
Ankle edema, flushing, HAAnkle edema, flushing, HA
Diuretic (Thiazide e.g. Diuretic (Thiazide e.g. HCTZ or HCTZ or Chlorthalidone)Chlorthalidone)
Low cost, edema, Low cost, edema, highly effective highly effective with ACE/ARBwith ACE/ARB
HypokalemiaHypokalemia
Check K+ at 2 weeks to 1 mo Check K+ at 2 weeks to 1 mo then annually. NAS diet.then annually. NAS diet.
©2013 MFMER | slide-35
Case 2: The Togolese Boy With DM1
A 7 year old boy presents with DKA to your rural mission hospital. He is from a village without electricity or running water in his home. His family lives on < $2/day per person. His father comes to you as medical director of the hospital & asks you to d/c his son home to die. You would
a)Become angry and give dad your “man up” pep talk
b)Find the funds for home monitoring and insulin admin.
c)Ask the chaplain to share with father and son our eternal hope in Jesus and d/c him per the father’s wishes
d)Keep him hospitalized and provide continued monitoring and insulin until stable and think about it later.
©2013 MFMER | slide-36
DM1 – The Present Reality
• Costs exceed household financial resources
• Life expectancy in low income country < 1 year
• If annual treatment costs are > 2/3 the country’s per capita income, treatment is not reasonable (without relief type aid).
• International attn focused on providing specifically for DM1 costs (c.f. http://www.un-ngls.org/IMG/pdf_MDGs_and_Diabetes_Factsheet.pdf)
©2013 MFMER | slide-37
27/05/2008
Geneva Health Forum
IMS-Health (IV)Sufficiency of diabetes medicines consumption per country
3,47%
13,17%
16,95%
5,16%
24,56%
2,87%
14,37%
6,08%
37,78%
19,35%
13,15%
2,73%
10,86%
6,63%
10,43%
6,62%
5,56%
1,82%
7,67%
3,29%
0% 5% 10% 15% 20% 25% 30% 35% 40%
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Total Oral
Insulin
Sufficiency (%)
©2013 MFMER | slide-38
Case 2b:The 70 year old Togolese Diabetic
A 70 yo man presents with polyuria to your rural mission hospital. He is from a village without electricity or running water. His family lives on < $2/day. You find no percussed suprapubic fullness over his bladder and a random glucose is 354. His exam is otherwise normal. You would
a)Advise weight loss, exercise, and 1 aspirin per day
b)“a” and add Metformin 2000 mg daily
c)Check a creatinine and do “b” if < 1.5
d)Do “c” and check his cholesterol and add a statin to control his LDL < 100
e)Do “d” and also add an ACE in case and recommend home glucose monitoring
©2013 MFMER | slide-39
Risk Reduction of Various Interventions Risk Reduction of Various Interventions - 1993- 1993
Increased cardiovascular risk in type 2 diabetes
Calculated effects of different interventions on coronary and total deaths in 1000 normal and 1000 men with type 2 diabetes aged 35 to 57 years without a history of myocardial infarction. Yudkin, JS, BMJ 1993; 306:1313
©2013 MFMER | slide-40
Conclusion Errors…
• The residual risk of “MRFIT” is due to high sugars
• Lowering sugar will eliminate the risk
• We should focus on frequently testing glucose and treating hyperglycemia
©2013 MFMER | slide-41
Value of Intensive Glycemic ControlValue of Intensive Glycemic Control3867 Type 2 DM followed 10 years3867 Type 2 DM followed 10 years
UKPDS 33, Lancet 1998
Conventional Control•Diet alone•A1C 7.9%
vs
Intensive Control•Diet + Sulfa or Insulin•A1C 7%
Less weight gain No difference in agent eff.
Less hypoglycemia 12% less laser photocoag of retinae
No sig difference in deaths
Conclusion: Tight control of DM2 doesn’t affect mortality (or help much).
©2013 MFMER | slide-42
ADVANCE:The End of Tight Control?
• 215 centers, 20 countries; U. of Sydney, AU
• 11,140 pts DM2 randomized to “tight” A1C 6.5% or standard A1C to 7.3%; f/u 5 years
• Age > 55, Vascular disease or risk
• No difference in CV death, nonfatal MI, stroke.
• Less macroalbuminuria (9.4% vs 10.9%)
• More hypoglycemia (2.7% vs 1.5%)
The ADVANCE Collaborative Group. INTENSIVE BLOOD GLUCOSE CONTROL AND VASCULAR OUTCOMES IN PATIENTS WITH TYPE 2 DIABETES. N Engl J Med 358(24):2560, June 12, 2008
©2013 MFMER | slide-43
ACCORD:The End of Tight Control?
• No significant different in MI or stroke
• Intensive treatment caused• Increased all-cause mortality 5% vs 4% (P=NS)• More Hypoglycemia 16.2% vs 5.1%• More Weight gain > 10 kg 27.8% vs 14.1%
The Action to Control Cardiovascular Risk in Diabetes (ACCORD) Study Group . The EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES. N Engl J Med 358(24):2545, June 12, 2008
©2013 MFMER | slide-44
The Big Point
• Summary of 50 years of type 2 diabetes research:
• Glycemic control has little to do with morbidity and mortality
• Obesity, inactivity, and other bad behaviors mitigate risk
• Correcting the real problems reduce risk.
©2013 MFMER | slide-45
Rational CV Risk Reduction Method:
• Smoking Cessation
• Med Diet, weight loss, exercise
• ASA
• BP normalization
• Statin (not lipid lowering)
• Glycemic control of minor benefit – use for symptoms unless well resourced.
• Self testing wasteful unless on insulin
©2013 MFMER | slide-47
27/05/2008
Geneva Health Forum
World Health Organization/ Health Action International (VII) – Cost of Meds Expressed in Days of Wages
A ffordability of one months therapy with the LP G of glibenclamide (5 mg, 2 times a day) and the LP G of metformin (500 mg, 3 times a day) in the private sector
0 1 2 3 4 5 6 7 8 9
Ethiopia (2004)Ghana (2004)
India-Chennai (2004)India-Haryana (2004)
India-Karnataka (2004)India-M aharashtra 12 districts (2004)India-M aharashtra 4 regions (2005)
India-Rajasthan (2003) India-West Bengal (2004)
Kenya (2004)M ongolia (2004)
Nigeria (2004)P akistan (2004)Tanzania (2004)
Sudan-Gadarif (2006)Sudan-Khartoum (2005)Sudan-Kordofan (2006)
Uganda (2004)Yemen (2006)
F iji (2004)Indonesia (2004)
J ordan (2004)M orocco (2004)
P eru (2005)P hilippines (2005)
Syria (2003)
Lebanon (2004)M alaysia (2004)
Kuwait (2004)United A rab Emirates (2006)
Affordability in days wages
M etformin500 mg
Glibenclamide5 mg
©2013 MFMER | slide-48
Cost Effective Care of DM2 in LIC
• One medication decreases mortality = Metformin
• Order of highest to lowest priority1. Reduce cardiac risk (see prior slide)2. Treat to reduce symptoms not A1C3. Retinal monitoring if affordable/treatment
available4. Microalbuminuria -> ACE if affordable5. Lower fasting glucose as income allows
©2013 MFMER | slide-49
Case 3: The Pregnant Pakistani Woman
A healthy 30 yo G2P1 with an uncomplicated last pregnancy delivered by trained TBA in her home presents for prenatal care to your rural hospital at 12 weeks GA. You would
a)Recommend monthly visits increasing to every 2 weeks at term with hospital delivery to be safest
b)Recommend she simply again deliver at home with the TBA
c)Recommend care at the maternity in town
d)Recommend TT2, iron/folate, insecticide treated bednet use, IPTp, a prenatal visit in each trimester with a midwife or physician and delivery with the midwife.
©2013 MFMER | slide-50
50
Why Be Involved
Institute of Medicine. The U.S. Commitment to Global Health: Recommendations for the New Administration Committee on the U.S. Commitment to Global Health. 2009.
©2013 MFMER | slide-57
57
Prenatal Care
►Requires 1 visit per trimester
►Interventions• Iron/Folate• Fansidar malaria treatment/prophylaxis• IT Bed nets• Tetanus immunization - TT2 • Advise location of delivery
©2013 MFMER | slide-59
Examining the Care Delivery Value Chain
• Prevention
• Testing/Screening
• Staging
• Delaying progression of disease
• Initiation of therapy
• Continuous disease management
• Management of deterioration
Rhatigan et al. Applying the Care Delivery Value Chain: HIV/AIDS Care in Resource Poor Setttings. Harvard Business School working paper, 2009
©2013 MFMER | slide-60
60
Cost Effectiveness: Prevention
• Lifestyle/public health• Latrines• Hand washing• Clean water (vs pills for NTD’s)• Insecticide treated bed nets• Smoking cessation• Weight loss• Exercise DM2, HTN• Med Diet
©2013 MFMER | slide-63
63
Cost Effectiveness: Prevention
• Lifestyle/public health• Latrines• Hand washing• Clean water (vs pills for NTD’s)• Insecticide treated bed nets• Smoking cessation• Weight loss• Exercise DM2, HTN• Med Diet • Aspirin CAD
©2013 MFMER | slide-64
64
Cost Effectiveness Diagnosis
• Limited labs Choose 1 or 2
• Limited imaging Use rarely
• Careful exam Yet efficient
• Rare specialists Textbooks or Virtual Consults
©2013 MFMER | slide-65
65
Empiric Rx: WHO IMCI(Integrated Management of Childhood Illness) – Syndromic Diagnoses
• Cough (and fever)
• Increased respiratory rate• ≥60 if age < 2 mos.• ≥50 if age 2-12 mos.• ≥40 if age 12 mos. to 5 years
• Lower chest retractions
• (Hypoxia, crackles, percussed
dullness rather than CXR)
= Pneumonia= Pneumonia
©2013 MFMER | slide-66
66
Cost Effectiveness• Treatment
• Lifestyle/public health Sustainable cheap
• Essential meds No fru-fru• Efficient treatment of chronic disease• Balance NNTB / NNTH Mental Math• Avoid futility End of
life care
©2013 MFMER | slide-67
67
Cost Effective Care
• Treatment• Lifestyle/public health Sustainable
cheap• Essential meds and meds only when
essential• No treatment for URI’s, most OM,
conjunctivitis, sinusitis, acute bronchitis• I & D not antibiotic for abscess• No expensive junk
©2013 MFMER | slide-68
68
Cost Effective Care
• Treatment• Lifestyle/public health Sustainable
cheap• Essential meds No fru-fru• Task Shifting - Increase access and lower
costs
©2013 MFMER | slide-71
71
Cost Effective Care
• Treatment• Lifestyle/public health Sustainable
cheap• Essential meds No fru-fru• Task Shifting Access• Efficient treatment of chronic disease
• Pills if treatment saves life for < 3 x per capita GNP (3 x personal income?)
©2013 MFMER | slide-72
72
Cost Effective Care• Treatment
• Lifestyle/public health Sustainable cheap
• Essential meds No fru-fru• Efficient treatment of chronic disease• Task Shifting Access• Balance NNTB / NNTH Mental Math
©2013 MFMER | slide-73
73
Cost Effective Care• Treatment
• Lifestyle/public health Sustainable cheap
• Essential meds No fru-fru• Efficient treatment of chronic disease• Task Shifting Access
• Balance NNTB / NNTH Mental Math• Avoid futility End of
life care
©2013 MFMER | slide-74
74
Cost Effective Care• Treatment
• Avoid futility - intensive care of terminal patients• Helping patients/families accept death
and place their trust in Jesus• Learning to die well – hospice, chaplains,
pastors, community
©2013 MFMER | slide-75
75
Cost Effective Care• Treatment
• Lifestyle/public health• Essential meds• Efficient treatment of chronic disease• Task Shifting • Balance NNTB / NNTH• Avoid futility
©2013 MFMER | slide-76
76
Actual Causes of Death2
Tobacco
Poor diet/lack of exercise3
Alcohol
Infectious agents
Pollutants/toxins
Firearms
Sexual behavior
Motor vehicles
Illicit drug use
Leading Causes of Death1
Percentage (of all deaths)
Heart Disease
Cancer
Chronic lower respiratory disease
Unintentional Injuries
Pneumonia/influenza
Diabetes
Alzheimer’s disease
Kidney Disease
Stroke
Percentage (of all deaths)
1 National Vital Statistics Reports, Vol. 53, No. 15, February 28, 2005.2 Adapted from McGinnis Foege, updated by Mokdad et. al., 2000.3 JAMA, April 20, 2005—Vol 293, No. 15, pg 1861.
Primary Health Care:Getting to the root of the problem
©2013 MFMER | slide-77
Case 4: The Anginal African Farmer
You’re seeing a 55 yo African small business owner who presents with angina. He smokes a few cigarettes per day, eats a reasonable diet though high salt. Exam shows a BMI of 33, BP 160/105, otherwise normal exam. In order of most to least importance, which of the following would you do?
a)Advise weight loss
b)Control HTN with a B-blocker
c)Smoking cessation
d)Lipid lowering to LDL < 70
e)Advise he exercise daily
©2013 MFMER | slide-78
Closing Thoughts
• Academic cost effectiveness analysis depends on presuppositions about benefits and harms.
• Docs in Cost Effective Care folder• HIV/AIDS meningitis care – Boulware et al• NCD’s in Asia BMJ and book chapter NCD’s• Best Buys• MDG’s and Diabetes – Interest group driven• Harvard Business School paper
©2013 MFMER | slide-79
Medical Missionaries Behaving Well
• Follow country MOH treatment protocols
• Focus on prevention
• Treat patients intelligently with regard to absolute benefits and all costs and the patient’s financial resources.
©2013 MFMER | slide-80
Learning Objectives
• Treat chronic diseases in adults and children in resource limited settings in a rational, cost-effective way.
• Follow an income and country GNP based protocol for hypertension, type 1 and 2 diabetes, hyperlipidemia, and coronary artery disease diagnosis and care.
• Design treatment protocols based on guiding principles of cost-effectiveness.
80